TY  - JOUR
T1  - RIver blindness trial
AU  - Stephenson J
Y1  - 2009/08/19
N1  - 10.1001/jama.2009.1158
JO  - JAMA
SP  - 732
EP  - 732
VL  - 302
IS  - 7
N2  - 
A newly launched phase 3 clinical trial will investigate whether moxidectin, a drug currently used to treat parasites in animals, can speed the elimination of onchocerciasis, or river blindness, one of the leading causes of blindness across Africa (http://apps.who.int/tdr/news-events/news/pdf/moxidectin-press-release.pdf). The Special Program for Research and Training in Tropical Diseases, which is administered by the World Health Organization, will conduct the trial with African investigators and institutions and enroll 1500 individuals at 4 sites in Ghana, Liberia, and the Democratic Republic of the Congo.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.1158
UR  - http://dx.doi.org/10.1001/jama.2009.1158
ER  -